Prediction Analysis of Microarray of 50 genes (PAM50) classifier validated for predicting prostate cancer progression in active surveillance: Miami Active Surveillance Trial (MAST).

Key Points

• This research aims to evaluate the effectiveness of the PAM50 classifier in predicting prostate cancer progression among men undergoing active surveillance.
• Conducted a prospective analysis of the PAM50 classifier in men with prostate cancer on active surveillance.
• Evaluated the basal-luminal subtyping for its predictive capability.
• Assessed progression risk using clinical parameters alongside molecular classification.
• The PAM50 classifier effectively categorized patients into subtypes associated with differing progression risks.
• Validation results indicate that PAM50 could be a reliable tool for monitoring cancer progression in active surveillance cohorts.